TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16062021

Group type: EXPERIMENTAL
Intervention: 0.5% 20 ml bupivacaine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.5% 20 ml bupivacaine with 1 microg/kg clonidine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12373696

Group type: COMPARATOR
Intervention: 8 mL of lidocaine‐bupivacaine mixture plus 0.5 mL 0.9% NaCl (group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 8 mL of lidocaine‐bupivacaine mixture plus 0.5 mL (5 mg) atracurium (group II)
Number of subjects: 60
Study: 10544340

Group type: EXPERIMENTAL
Intervention: Tetracycline eye ointment administered by Village Treatment Assistants (VTAs) daily for four weeks.
Number of subjects: 280
Study: 8552458

Group type: EXPERIMENTAL
Intervention: Original faces (unmanipulated)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manipulated faces (various manipulations including mirror reversal, pseudo-cardioidal strain, thresholding, and elimination of internal features)
Number of subjects: 50
Study: 2093019

Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 or 40 mg daily
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg daily (maintenance)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Ranitidine, 150 mg b.i.d.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Omeprazole weekend therapy (20 mg daily on Fri, Sat, Sun)
Number of subjects: 63
Study: 74302

Group type: EXPERIMENTAL
Intervention: Combination schedule containing adriamycin
Number of subjects: 71

Group type: COMPARATOR
Intervention: Combination schedule without adriamycin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Prior radiotherapy
Number of subjects: 71
Study: 31712621

Group type: EXPERIMENTAL
Intervention: Microbeads loaded with amino acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantum dot labels introduced into microbeads
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluorescence imaging and data analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical removal of microbeads from microwells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stochastic monomer patterning
Number of subjects: 0
Study: 27393428

Group type: COMPARATOR
Intervention: Reference product (A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Test product (B)
Number of subjects: 18
Study: 24346096

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus carboplatin (nab-P/C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: sb-paclitaxel plus carboplatin (sb-P/C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician assessment of peripheral neuropathy
Number of subjects: 0
Study: 23895539

Group type: EXPERIMENTAL
Intervention: Hilotherm cooling face mask
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional cooling compresses
Number of subjects: 42
Study: 20665254

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) applied to the posterior cerebellum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline conditions (no rTMS)
Number of subjects: 0
Study: 18724649

Group type: EXPERIMENTAL
Intervention: Tretinoin microsphere gel 0.04%
Number of subjects: 245

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 245
Study: 15917009

Group type: EXPERIMENTAL
Intervention: Leaflet about the threat of cervical cancer from smoking and the benefits to cervical health in stopping, containing a detailed explanation of how smoking harms the cervix
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Leaflet about the threat of cervical cancer from smoking and the benefits to cervical health in stopping, without the detailed explanation
Number of subjects: 330

Group type: COMPARATOR
Intervention: No leaflet
Number of subjects: 330
Study: 12810614

Group type: EXPERIMENTAL
Intervention: D-dimer levels
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Fibrinogen and serum amyloid A (SAA) levels
Number of subjects: 601
Study: 10629345

Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin
Number of subjects: 3950

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 3950

Group type: COMPARATOR
Intervention: Placebo or no antithrombotic therapy
Number of subjects: 3950
Study: 1994417

Group type: EXPERIMENTAL
Intervention: Oral superparamagnetic contrast agent (800 mL ingested over approximately 2 hours)
Number of subjects: 62
Study: 6823617

Group type: EXPERIMENTAL
Intervention: Active therapist role (highly verbal and directive)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Passive therapist role (minimally verbal or directive)
Number of subjects: 28
Study: 30778865

Group type: EXPERIMENTAL
Intervention: Macrovascular complications - Myocardial infarction (MI)
Number of subjects: 8713

Group type: EXPERIMENTAL
Intervention: Macrovascular complications - Congestive heart failure (CHF)
Number of subjects: 8713

Group type: EXPERIMENTAL
Intervention: Macrovascular complications - Stroke
Number of subjects: 8713

Group type: EXPERIMENTAL
Intervention: Macrovascular complications - Angina
Number of subjects: 8713

Group type: EXPERIMENTAL
Intervention: Macrovascular complications - Revascularization surgery (RS)
Number of subjects: 8713

Group type: EXPERIMENTAL
Intervention: Microvascular complications - Severe vision loss
Number of subjects: 8713

Group type: EXPERIMENTAL
Intervention: Microvascular complications - Severe pressure sensation loss
Number of subjects: 8713

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (both severe and symptomatic)
Number of subjects: 8713
Study: 30644302

Group type: EXPERIMENTAL
Intervention: arthroscopic debridement and a subsequent intra‐articular injection of autologous micro‐fragmented adipose tissue
Number of subjects: 39

Group type: COMPARATOR
Intervention: arthroscopic debridement
Number of subjects: 39
Study: 26691932

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied immediately after extraction
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no LLLT applied)
Number of subjects: 22
Study: 24504571

Group type: EXPERIMENTAL
Intervention: Low stress
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Medium stress
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High stress
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Position effect
Number of subjects: 50
Study: 21692147

Group type: EXPERIMENTAL
Intervention: Right hippocampal activity during successful face-name association learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right hippocampal activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theoretical formulations regarding medial temporal contributions
Number of subjects: 0
Study: 20532650

Group type: EXPERIMENTAL
Intervention: Affective self-awareness (ASA) intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 45
Study: 17599424

Group type: EXPERIMENTAL
Intervention: Lowering low-density lipoprotein cholesterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reducing systolic blood pressure to <140 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lowering systolic blood pressure to <120 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycemic control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive therapy for diabetes-related dyslipidemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal blood pressure control
Number of subjects: 0
Study: 16291347

Group type: EXPERIMENTAL
Intervention: Intrauterine growth restriction (IUGR) infants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 0
Study: 11988199

Group type: EXPERIMENTAL
Intervention: Dobutamine stress MRI
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Patients with surgically corrected TGA
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Patients with congenitally corrected TGA
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Patients with subpulmonic right ventricles
Number of subjects: 47
Study: 9859856

Group type: EXPERIMENTAL
Intervention: Dutch Sleep Disorders Questionnaire (SDQ)
Number of subjects: 145
Study: 7488484

Group type: EXPERIMENTAL
Intervention: vecuronium 0.1 mg kg‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: suxamethonium 1 mg kg‐1
Number of subjects: 20
Study: 2012453

Group type: EXPERIMENTAL
Intervention: Full-dosage zidovudine (1200 mg/d)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Reduced dosage zidovudine (600 mg/d)
Number of subjects: 86

Group type: COMPARATOR
Intervention: No dosage change
Number of subjects: 86
Study: 7258744

Group type: EXPERIMENTAL
Intervention: Combination drug product containing triprolidine and pseudoephedrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31430763

Group type: EXPERIMENTAL
Intervention: 670 nm red light treatment (15 min daily until 34 weeks corrected age, 9 J/cm2)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no red light)
Number of subjects: 86
Study: 31779461

Group type: EXPERIMENTAL
Intervention: Scharioth macular lens (SML) implantation with transcranial electrical stimulation (tES)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 20
Study: 29037354

Group type: EXPERIMENTAL
Intervention: HP802‐247 (allogeneic living cell therapy consisting of growth‐arrested human keratinocytes and fibroblasts)
Number of subjects: 716

Group type: COMPARATOR
Intervention: Standard therapy with compression bandaging (control)
Number of subjects: 716
Study: 26930375

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Botulinum toxin type A (BoNT‐A)
Number of subjects: 72
Study: 24681712

Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 6854

Group type: COMPARATOR
Intervention: Minimally invasive surgery
Number of subjects: 6854

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 6854

Group type: EXPERIMENTAL
Intervention: Laparotomy and laparoscopic cases
Number of subjects: 6854

Group type: EXPERIMENTAL
Intervention: Surgical site infection (SSI)
Number of subjects: 6854
Study: 22316314

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation (average daily dose 10,200 IU)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low-dose vitamin D supplementation (average daily dose 200 IU)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low-dose vitamin D supplementation
Number of subjects: 80
Study: 19174529

Group type: EXPERIMENTAL
Intervention: Home telemonitoring
Number of subjects: 182

Group type: COMPARATOR
Intervention: Usual specialist care
Number of subjects: 182
Study: 17804033

Group type: EXPERIMENTAL
Intervention: High-pass filtered random dot kinematograms (RDKs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfiltered random dot kinematograms (RDKs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age-matched control group
Number of subjects: 0
Study: 15101856

Group type: EXPERIMENTAL
Intervention: Ropivacaine-HCl 5 mg ml(-1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Levobupivacaine-HCl 5 mg ml(-1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bupivacaine-HCl 5 mg ml(-1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: All groups (Ropivacaine, Levobupivacaine, Bupivacaine)
Number of subjects: 90
Study: 12221843

Group type: EXPERIMENTAL
Intervention: Medication plus carbon dioxide baths
Number of subjects: 63

Group type: COMPARATOR
Intervention: Medication only
Number of subjects: 63
Study: 9818665

Group type: EXPERIMENTAL
Intervention: Intraarticular hyaluronic acid (HA; Hyalgan) 20 mg each for 5 weekly injections
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Intraarticular hyaluronic acid (HA; Hyalgan)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495

Group type: COMPARATOR
Intervention: Oral naproxen
Number of subjects: 495
Study: 8131527

Group type: EXPERIMENTAL
Intervention: Terbutaline dry powder inhaled via Turbuhaler (2.5 mg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Terbutaline inhaled via CFC inhaler and Nebuhaler (2.5 mg)
Number of subjects: 68
Study: 2401100

Group type: EXPERIMENTAL
Intervention: Naloxone, 4 mg bolus and 6 mg/h intravenously
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline, administered intravenously
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Naloxone, administered intravenously
Number of subjects: 11
Study: 7437134

Group type: EXPERIMENTAL
Intervention: FK 33‐824 (1.25 mg, i.m.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Morphine HCL (20 mg, i.m.)
Number of subjects: 8
Study: 31164707

Group type: EXPERIMENTAL
Intervention: Top quarter of vitamin A
Number of subjects: 9658

Group type: EXPERIMENTAL
Intervention: Top quarter of vitamin E
Number of subjects: 9658

Group type: EXPERIMENTAL
Intervention: Vitamin A levels change from low (1.53) to high (1.95) in low BMI category
Number of subjects: 9658

Group type: EXPERIMENTAL
Intervention: Vitamin A levels change from low (1.53) to high (1.95) in high BMI category
Number of subjects: 9658
Study: 27910088

Group type: EXPERIMENTAL
Intervention: Bupivacaine (GON blockade administered four times, once per week)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (saline, GON blockade administered four times, once per week)
Number of subjects: 44
Study: 25688820

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (1 gram)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 24388090

Group type: EXPERIMENTAL
Intervention: Unicirc disposable instrument plus tissue adhesive
Number of subjects: 150

Group type: COMPARATOR
Intervention: Open surgical circumcision with suturing
Number of subjects: 150
Study: 21867389

Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper (ABS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional technique (HCT)
Number of subjects: 61
Study: 19154853

Group type: EXPERIMENTAL
Intervention: Self-help booklets
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 17142002

Group type: EXPERIMENTAL
Intervention: Fast RPLC-UV method for tenoxicam assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bioanalytical study of tenoxicam
Number of subjects: 0
Study: 15167329

Group type: EXPERIMENTAL
Intervention: Computerized prompting of diabetes care
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Home glucose records in computer‐assisted insulin dose adjustment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pocket‐sized insulin dosage computers
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Computerized educational programs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Computer‐assisted interventions
Number of subjects: 40
Study: 11283424

Group type: EXPERIMENTAL
Intervention: Weight loss group (WG): restrict energy intake by 500 kcal x d(‐1) and exercise for 45 min x d(‐1), 4 d x wk(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss group (WG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study: 9484382

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 60 mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Meperidine 50 mg plus promethazine 25 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 41
Study: 8045501

Group type: EXPERIMENTAL
Intervention: Proximal splenorenal shunting
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Esophagogastric devascularization with splenectomy
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunting
Number of subjects: 94

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 94
Study: 2547622

Group type: EXPERIMENTAL
Intervention: cis‐platinum‐vindesine (P‐VDS)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: cis‐platinum‐VP16 (P‐VP16)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: cis‐platinum‐vindesine (P‐VDS) with radiotherapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: cis‐platinum‐VP16 (P‐VP16) with radiotherapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Karnofsky score of 80% or more
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 3‐week split interval
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both regimens (P‐VDS and P‐VP16)
Number of subjects: 72
Study: 989370

Group type: EXPERIMENTAL
Intervention: 1 mg haloperidol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 mg loxapine
Number of subjects: 40

Group type: COMPARATOR
Intervention: loxapine
Number of subjects: 40
Study: 30951772

Group type: EXPERIMENTAL
Intervention: EXERCISE (1 hour of hard aerobic exercise)
Number of subjects: 40

Group type: COMPARATOR
Intervention: REST (no exercise)
Number of subjects: 40
Study: 27506803

Group type: EXPERIMENTAL
Intervention: vBloc therapy
Number of subjects: 123

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 123
Study: 25573655

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Number of subjects: 2397

Group type: COMPARATOR
Intervention: Diabetes Support and Education
Number of subjects: 2397
Study: 23590647

Group type: EXPERIMENTAL
Intervention: Psychoprophylaxis childbirth preparation (coaching training)
Number of subjects: 762

Group type: COMPARATOR
Intervention: Standard care antenatal preparation (no coaching training)
Number of subjects: 762
Study: 21406094

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 100 mcg twice daily started at induction of anaesthesia and continued for 72 hours thereafter
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 100 mcg twice daily
Number of subjects: 360
Study: 19211261

Group type: EXPERIMENTAL
Intervention: IABP pulsatile CPB (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard linear CPB (group B)
Number of subjects: 40
Study: 16890832

Group type: EXPERIMENTAL
Intervention: Scheduled treatment interruptions
Number of subjects: 430

Group type: COMPARATOR
Intervention: Continuous treatment
Number of subjects: 430
Study: 14625204

Group type: COMPARATOR
Intervention: Lean men
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overweight men
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Obese men
Number of subjects: 15
Study: 11348958

Group type: EXPERIMENTAL
Intervention: Model Building (MB) group
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Model Validation (MV) group
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: APACHE III score
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Use of pressors
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Acute renal failure (ARF)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation, ARF, bronchoscopy, bacteremia, use of pressors, TIPS, never received CPR
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Source of admission, platelet transfusion, bacteremia, pneumonia, never received CPR
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation, platelet transfusion, bronchoscopy, TIPS, sepsis, never received CPR
Number of subjects: 582
Study: 9205938

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7950501

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 94

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 94
Study: 3324917

Group type: EXPERIMENTAL
Intervention: Preoperative shower with Chlorhexidine soap
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Local washing
Number of subjects: 1530

Group type: COMPARATOR
Intervention: No washing
Number of subjects: 1530
Study: 29159603

Group type: EXPERIMENTAL
Intervention: Prophylactic intraperitoneal onlay mesh stripe (IPOM) in Group A
Number of subjects: 267

Group type: COMPARATOR
Intervention: No additional mesh stripe in Group B (control)
Number of subjects: 267
Study: 27070542

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24962326

Group type: EXPERIMENTAL
Intervention: In-Prison buprenorphine Treatment Condition
Number of subjects: 211
Study: 24342495

Group type: EXPERIMENTAL
Intervention: Antithrombin at a dose of 30 IU/kg per day for three days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Antithrombin treatment
Number of subjects: 60
Study: 21323123

Group type: EXPERIMENTAL
Intervention: Good memorizers (Verbal Memory scores >110)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal memorizers
Number of subjects: 24
Study: 17394534

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Insulin and Glibenclamide
Number of subjects: 49
Study: 17300951

Group type: EXPERIMENTAL
Intervention: Atorvastatin plus aspirin combined therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 0
Study: 14740521

Group type: EXPERIMENTAL
Intervention: CT-based navigation system
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 80
Study: 10965090

Group type: EXPERIMENTAL
Intervention: On-line vectorcardiography (VCG) monitoring for 24 hours
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: On-line vectorcardiography (VCG) monitoring
Number of subjects: 150
Study: 8783345

Group type: EXPERIMENTAL
Intervention: Teicoplanin 10 mg/kg/day (Group A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Teicoplanin 20 mg/kg/day (Group B)
Number of subjects: 21